{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:59:46Z","timestamp":1780451986125,"version":"3.54.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Mazdutide, a glucagon-like peptide-1\/glucagon receptor (GLP - 1\/GCGR) dual agonist, has shown marked efficacy in glycemic control, weight loss, and metabolic improvement in adults. However, data in adolescents remain limited. This report explores its therapeutic potential in an adolescent with obesity-related type 2 diabetes mellitus (T2DM) and hyperuricemia (HUA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design and methods<\/jats:title><jats:p>We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg\/m\u00b2), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 \u03bcmol\/L). The patient underwent a dose-escalation regimen of Mazdutide (2 mg \u2192 4 mg \u2192 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 36 weeks, the patient showed significant improvement: weight decreased by 16.8 kg (18.89% BMI reduction), uric acid dropped by 37.00%, and HbA1c fell by 21.88%. No hypoglycemic episodes occurred. Lipid levels improved notably: triglycerides fell by 69.02%, total cholesterol by 13.65%, and LDL cholesterol by 17.27%. Hepatic steatosis resolved by week 14, as confirmed by ultrasound. No adverse events were reported, and benefits were sustained post-treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mazdutide exhibited robust metabolic efficacy and good tolerability in an adolescent with obesity, T2DM, and HUA. It improved glycemic control, reduced weight and uric acid, reversed steatosis, and modulated lipid profiles. These findings support its potential as a comprehensive treatment for adolescent metabolic disorders.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1654506","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:12:50Z","timestamp":1757909570000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1\/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenfei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00374-6","article-title":"Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis","volume":"6","author":"Noubiap","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.01.015","article-title":"Sugar-sweetened beverages, serum uric acid, and blood pressure in adolescents","volume":"154","author":"Nguyen","year":"2009","journal-title":"J Pediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e318183fd7c","article-title":"Serum uric acid and ambulatory blood pressure in children with primary hypertension","volume":"64","author":"Jones","year":"2008","journal-title":"Pediatr Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00645-1","article-title":"Youth-onset type 2 diabetes mellitus: an urgent challenge","volume":"19","author":"Bjornstad","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000510941","article-title":"Treatment of metabolic syndrome in children","volume":"93","author":"Tagi","year":"2020","journal-title":"Horm Res Paediat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2015.07.012","article-title":"Body composition changes in adolescents after laparoscopic sleeve gastrectomy","volume":"12","author":"Dubnov-Raz","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000524002","article-title":"Metabolic and bariatric surgery in adolescents: for whom, when, and how","volume":"96","author":"Janson","year":"2023","journal-title":"Horm Res Paediat"},{"key":"B9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12887-021-03051-x","article-title":"Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database","volume":"21","author":"Honda","year":"2021","journal-title":"BMC Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of mazdutide in chinese patients with type 2 diabetes: A randomized, double-Blind, placebo-Controlled phase 2 trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101691","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1309118","article-title":"Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Nalisa","year":"2024","journal-title":"Front Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in chinese adults with obesity or overweight","author":"Ji","year":"2025","journal-title":"New Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/db23-77-LB","article-title":"A novel glucagon-like peptide-1 (GLP-1R) and glucagon (GCGR) receptor dual agonist, mazdutide (IBI362), attenuates hyperuricemia in hyperuricemic rats","volume":"72","author":"Jiang","year":"2023","journal-title":"Diabetes"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1654506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:12:51Z","timestamp":1757909571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1654506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":15,"alternative-id":["10.3389\/fendo.2025.1654506"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1654506","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1654506"}}